Neutral
Last updated: 2026-08-20 08:01:32 ET
Pulse AI Brief
Updated Aug 20, 2026 7:02 AM ET
Moderna's stock rallied 177% as the company shifted focus from collapsing COVID-19 vaccine demand to oncology and personalized cancer treatments. The pivot demonstrates the company's ability to redeploy its mRNA platform beyond pandemic applications.
Biotech sector gains from Moderna's success in platform diversification; oncology-focused peers face new competition. Investors now price in multi-year cancer trial catalysts and potential blockbuster approvals.
Validates mRNA technology's broader therapeutic potential beyond infectious disease. Success here could accelerate adoption of personalized medicine and justify premium valuations for platform biotechs.
CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big win for mRNA vaccines ag...
Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, joins "The Takeout" to discuss the Trump administration's touting of l...
The biopharmaceutical sector has struggled with a prolonged downturn in recent years but has been on an upswing of late.
The Trump administration’s ‘America first’ approach has contributed to the scale of the crisis now unfolding in one of the world’s poorest cou...
Overton has said that Congress should strictly regulate abortion drug mifepristone ‘to protect women and children’Donald Trump nominated Dr Heidi ...
Kindergarten vaccine exemptions hit a record high last year in the U.S., according to Centers for Disease Control and Prevention data. Dr. Celine Goun...
Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Sen. Bill Cassidy blasted President Donald Trump's recent executive order that calls for unbundling the childhood MMR vaccine into three individual shots.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE